Halozyme Therapeutics, Inc. HALO Stock Forecast
AI-powered price prediction and analysis for Halozyme Therapeutics, Inc. ยท Updated Sep 22, 2026
See HALO's Exact Price Target
Create a free account and follow this stock to unlock its full AI forecast โ 3 stocks free.
Sign Up Free with GooglePrice Chart
Key Statistics
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) operates in the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. .
We do not have any company description for HALOZYME THERAPEUTICS, INC. at the moment.
Latest News
Where HALO sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | Ticker | AI Signal | Market Cap | P/E |
|---|---|---|---|---|
| Halozyme Therapeutics, Inc. | HALO | โโ% | $12.65B | 30.6x |
| Amgen Inc | AMGN | โโ% | $212.55B | 24.3x |
| Gilead Sciences, Inc. | GILD | โโ% | $186.69B | -x |
| Moderna, Inc. | MRNA | โโ% | $61.50B | -x |
| Argenx Se | ARGX | โโ% | $61.15B | -x |
| Revolution Medicines, Inc. | RVMD | โโ% | $40.93B | -x |
| Biogen Inc. | BIIB | โโ% | $32.34B | 23.6x |
| Biontech Se | BNTX | โโ% | $24.78B | -x |
| Mesoblast Ltd | MESO | โโ% | $19.62B | -x |
| Neurocrine Biosciences Inc | NBIX | โโ% | $14.86B | 21.1x |
| Exelixis, Inc. | EXEL | โโ% | $14.18B | -x |
| Bio-Techne Corp | TECH | โโ% | $11.35B | 62.4x |
| Twist Bioscience Corp | TWST | โโ% | $10.47B | -x |
| Repligen Corp | RGEN | โโ% | $9.98B | 240.3x |
| Krystal Biotech, Inc. | KRYS | โโ% | $9.88B | 40.9x |
| Kymera Therapeutics, Inc. | KYMR | โโ% | $9.78B | -x |
| Qiagen N.V. | QGEN | โโ% | $9.40B | -x |
| Immunitybio, Inc. | IBRX | โโ% | $8.96B | -x |
| Vaxcyte, Inc. | PCVX | โโ% | $8.65B | -x |
| Immunovant, Inc. | IMVT | โโ% | $7.68B | -x |
| Cg Oncology, Inc. | CGON | โโ% | $6.94B | -x |
| Scholar Rock Holding โฆ | SRRK | โโ% | $5.68B | -x |
| Crispr Therapeutics Ag | CRSP | โโ% | $5.64B | -x |
| Iovance Biotherapeutics, Inc. | IOVA | โโ% | $4.62B | -x |
| Adaptive Biotechnologies Corp | ADPT | โโ% | $4.45B | -x |
| Relay Therapeutics, Inc. | RLAY | โโ% | $4.13B | -x |
| Dbv Technologies S.A. | DBVT | โโ% | $3.58B | -x |
| Tarsus Pharmaceuticals, Inc. | TARS | โโ% | $3.43B | -x |
| Denali Therapeutics Inc. | DNLI | โโ% | $3.27B | -x |
| Beam Therapeutics Inc. | BEAM | โโ% | $2.61B | -x |
| Biocryst Pharmaceuticals Inc | BCRX | โโ% | $2.24B | -x |
| Scinai Immunotherapeutics Ltd. | SCNI | โโ% | $2.16B | -x |
| Adma Biologics, Inc. | ADMA | โโ% | $2.13B | 12.6x |
| Recursion Pharmaceuticals, Inc. | RXRX | โโ% | $2.05B | -x |
| Vericel Corp | VCEL | โโ% | $2.05B | 84.6x |
| Kodiak Sciences Inc. | KOD | โโ% | $2.04B | -x |
| Alvotech | ALVO | โโ% | $1.83B | -x |
| Vir Biotechnology, Inc. | VIR | โโ% | $1.79B | -x |
| Hemab Therapeutics Holdings, โฆ | COAG | โโ% | $1.77B | -x |
| Novavax Inc | NVAX | โโ% | $1.67B | -x |
| Immunocore Holdings Plc | IMCR | โโ% | $1.66B | -x |
| Taysha Gene Therapies, โฆ | TSHA | โโ% | $1.64B | -x |
| Cullinan Therapeutics, Inc. | CGEM | โโ% | $1.37B | -x |
| Meiragtx Holdings Plc | MGTX | โโ% | $1.27B | 16.1x |
| Vor Biopharma Inc. | VOR | โโ% | $1.27B | -x |
| Maze Therapeutics, Inc. | MAZE | โโ% | $1.25B | -x |
| Replimune Group, Inc. | REPL | โโ% | $1.23B | -x |
| Zura Bio Ltd | JATT | โโ% | $1.17B | -x |
| Odyssey Therapeutics, Inc. | ODTX | โโ% | $1.17B | -x |
| Immatics N.V. | IMTX | โโ% | $1.17B | -x |
| Valneva Se | VALN | โโ% | $1.14B | -x |
| Monte Rosa Therapeutics, โฆ | GLUE | โโ% | $1.05B | -x |
| Solid Biosciences Inc. | SLDB | โโ% | $955M | -x |
| Sana Biotechnology, Inc. | SANA | โโ% | $928M | -x |
| Candel Therapeutics, Inc. | CADL | โโ% | $858M | -x |
| 4d Molecular Therapeutics, โฆ | FDMT | โโ% | $841M | -x |
| Aura Biosciences, Inc. | AURA | โโ% | $660M | -x |
| Allogene Therapeutics, Inc. | ALLO | โโ% | $584M | -x |
| Prime Medicine, Inc. | PRME | โโ% | $566M | -x |
| Ginkgo Bioworks Holdings, โฆ | DNA | โโ% | $537M | -x |
FAQ
-
Is Halozyme Therapeutics, Inc. a good stock to buy?
Our AI analyzes Halozyme Therapeutics, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
-
How accurate are Halozyme Therapeutics, Inc. predictions?
A per-ticker accuracy statistic for HALO is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
-
How often are forecasts updated?
Halozyme Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 22, 2026.
Ready to invest smarter?
Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Halozyme Therapeutics, Inc.?
View full institutional-grade analysis on Intratio โAI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.